JP2008520241A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008520241A5 JP2008520241A5 JP2007543209A JP2007543209A JP2008520241A5 JP 2008520241 A5 JP2008520241 A5 JP 2008520241A5 JP 2007543209 A JP2007543209 A JP 2007543209A JP 2007543209 A JP2007543209 A JP 2007543209A JP 2008520241 A5 JP2008520241 A5 JP 2008520241A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- medicament according
- antibody fragment
- domain
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Claims (5)
- エンドセリン−1/アンジオテンシンII二重レセプター(Dear)ET−1ドメインへの結合をブロッキングできる抗体または抗体フラグメントを含む、個体における血管新生を阻害するための医薬。
- 抗体または抗体フラグメントがヒト化抗体またはヒト化抗体フラグメントである、請求項1に記載の医薬。
- 血管新生は、免疫および非免疫炎症、慢性関節リューマチ、乾癬、糖尿病性網膜症、血管新生緑内症、再発狭窄症、黄班変性、アテローム性動脈硬化プラークにおける毛細管増殖、骨粗鬆症、癌、充実性腫瘍、充実性腫瘍転移、血管線維腫、水晶体後方線維増殖症、血管腫およびカポジ肉腫からなる群より選ばれる疾患または障害と関連している、請求項1に記載の医薬。
- 抗体または抗体フラグメントが配列番号2のET−1ドメインへの結合をブロッキングする、請求項1に記載の医薬。
- ET−1ドメインが配列番号2のアミノ酸60〜67を含む、請求項1に記載の医薬。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US62844704P | 2004-11-16 | 2004-11-16 | |
US60/628,447 | 2004-11-16 | ||
US69426805P | 2005-06-27 | 2005-06-27 | |
US60/694,268 | 2005-06-27 | ||
PCT/US2005/041594 WO2006055665A2 (en) | 2004-11-16 | 2005-11-15 | Roles for dual endothelin-1/angiotensin ii receptor (dear) in hypertension and angiogenesis |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012168420A Division JP2012233000A (ja) | 2004-11-16 | 2012-07-30 | 高血圧および血管新生におけるエンドセリン−1/アンジオテンシンii二重レセプター(dear)の役割 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2008520241A JP2008520241A (ja) | 2008-06-19 |
JP2008520241A5 true JP2008520241A5 (ja) | 2011-03-17 |
JP5341350B2 JP5341350B2 (ja) | 2013-11-13 |
Family
ID=36407731
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007543209A Active JP5341350B2 (ja) | 2004-11-16 | 2005-11-15 | 高血圧および血管新生におけるエンドセリン−1/アンジオテンシンii二重レセプター(dear)の役割 |
JP2012168420A Pending JP2012233000A (ja) | 2004-11-16 | 2012-07-30 | 高血圧および血管新生におけるエンドセリン−1/アンジオテンシンii二重レセプター(dear)の役割 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012168420A Pending JP2012233000A (ja) | 2004-11-16 | 2012-07-30 | 高血圧および血管新生におけるエンドセリン−1/アンジオテンシンii二重レセプター(dear)の役割 |
Country Status (6)
Country | Link |
---|---|
US (3) | US7919093B2 (ja) |
EP (2) | EP1812473A4 (ja) |
JP (2) | JP5341350B2 (ja) |
AU (1) | AU2005307765C1 (ja) |
CA (1) | CA2588066A1 (ja) |
WO (1) | WO2006055665A2 (ja) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2390425T3 (es) * | 2000-12-22 | 2012-11-12 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Uso de moléculas de orientación repulsivas (RGM) y sus moduladores |
EP1928905B1 (de) * | 2005-09-30 | 2015-04-15 | AbbVie Deutschland GmbH & Co KG | Bindungsdomänen von proteinen der repulsive guidance molecule (rgm) proteinfamilie und funktionale fragmente davon sowie deren verwendung |
ES2550004T3 (es) | 2006-04-04 | 2015-11-03 | Singulex, Inc. | Sistema de alta sensibilidad y métodos de análisis de la troponina |
US7838250B1 (en) | 2006-04-04 | 2010-11-23 | Singulex, Inc. | Highly sensitive system and methods for analysis of troponin |
EP2033971A1 (de) * | 2007-09-06 | 2009-03-11 | Abbott GmbH & Co. KG | Bone Morphogenetic Protein (BMP)-bindende Domänen von Proteinen der Repulsive Guidance Molecule (RGM) Proteinfamilie und funktionale Fragmente davon sowie deren Verwendung |
US8962803B2 (en) * | 2008-02-29 | 2015-02-24 | AbbVie Deutschland GmbH & Co. KG | Antibodies against the RGM A protein and uses thereof |
AU2010259022B2 (en) | 2009-06-08 | 2016-05-12 | Singulex, Inc. | Highly sensitive biomarker panels |
MX2012006560A (es) * | 2009-12-08 | 2012-10-05 | Abbott Gmbh & Co Kg | Anticuerpos monoclonales contra la proteina rgm a para utilizarse en el tratamiento de degeneracion de capa de fibra de nervio retinal. |
WO2012012750A1 (en) * | 2010-07-23 | 2012-01-26 | Trustees Of Boston University | ANTI-DEsupR INHIBITORS AS THERAPEUTICS FOR INHIBITION OF PATHOLOGICAL ANGIOGENESIS AND TUMOR CELL INVASIVENESS AND FOR MOLECULAR IMAGING AND TARGETED DELIVERY |
US20130022551A1 (en) * | 2011-07-22 | 2013-01-24 | Trustees Of Boston University | DEspR ANTAGONISTS AND AGONISTS AS THERAPEUTICS |
MX352772B (es) | 2012-01-27 | 2017-12-07 | Abbvie Deutschland | Composición y método para el diagnóstico y tratamiento de enfermedades asociadas con la degeneración de neuritas. |
AU2016311265B2 (en) * | 2015-08-24 | 2023-03-16 | Trustees Of Boston University | Anti-DEspR monoclonal antibody targeted therapy and imaging for cancer and stroke |
JP7404230B2 (ja) | 2017-09-18 | 2023-12-25 | トラスティーズ オブ ボストン ユニバーシティ | ネトーシスおよび好中球活性化を処置するための方法 |
US10953107B2 (en) | 2018-06-15 | 2021-03-23 | Trustees Of Boston University | Polypeptide compositions and methods for site-specific targeting of therapeutic agents |
WO2022081792A1 (en) | 2020-10-15 | 2022-04-21 | Trustees Of Boston University | Antibody therapies and methods for treating coronavirus infection |
CN116530469B (zh) * | 2023-07-06 | 2023-09-19 | 首都医科大学 | 腹主动脉瘤动物模型的制备方法与应用 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3625214A (en) | 1970-05-18 | 1971-12-07 | Alza Corp | Drug-delivery device |
US4486530A (en) | 1980-08-04 | 1984-12-04 | Hybritech Incorporated | Immunometric assays using monoclonal antibodies |
US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
US4411993A (en) | 1981-04-29 | 1983-10-25 | Steven Gillis | Hybridoma antibody which inhibits interleukin 2 activity |
US4543439A (en) | 1982-12-13 | 1985-09-24 | Massachusetts Institute Of Technology | Production and use of monoclonal antibodies to phosphotyrosine-containing proteins |
US4906474A (en) | 1983-03-22 | 1990-03-06 | Massachusetts Institute Of Technology | Bioerodible polyanhydrides for controlled drug delivery |
US4902614A (en) | 1984-12-03 | 1990-02-20 | Teijin Limited | Monoclonal antibody to human protein C |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4789734A (en) | 1985-08-06 | 1988-12-06 | La Jolla Cancer Research Foundation | Vitronectin specific cell receptor derived from mammalian mesenchymal tissue |
NO870613L (no) | 1986-03-05 | 1987-09-07 | Molecular Diagnostics Inc | Deteksjon av mikroorganismer i en prve inneholdende nukleinsyre. |
EP0318512B1 (en) | 1986-08-18 | 1998-06-17 | Emisphere Technologies, Inc. | Delivery systems for pharmacological agents |
DE68928853T2 (de) | 1988-05-20 | 1999-08-05 | Cetus Corp | Befestigung von sequenzspezifischen proben |
US5410016A (en) | 1990-10-15 | 1995-04-25 | Board Of Regents, The University Of Texas System | Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers |
US5440021A (en) * | 1991-03-29 | 1995-08-08 | Chuntharapai; Anan | Antibodies to human IL-8 type B receptor |
ATE198358T1 (de) | 1992-04-27 | 2001-01-15 | Dartmouth College | Detektion von gensequenzen in biologischen flüssigkeiten |
US5593688A (en) | 1993-06-25 | 1997-01-14 | Nexstar Pharmaceuticals, Inc. | Liposomal targeting of ischemic tissue |
DE69433180T2 (de) | 1993-10-26 | 2004-06-24 | Affymetrix, Inc., Santa Clara | Felder von nukleinsaeuresonden auf biologischen chips |
EP0897567A2 (en) | 1996-04-19 | 1999-02-24 | Spectra Biomedical, Inc. | Correlating polymorphic forms with multiple phenotypes |
EP0979869A1 (en) | 1998-08-07 | 2000-02-16 | Hoechst Marion Roussel Deutschland GmbH | Short oligonucleotides for the inhibition of VEGF expression |
US6641811B1 (en) * | 2000-02-10 | 2003-11-04 | Cornell Research Foundation, Inc. | Use of angiotensin II inhibitors to prevent malignancies associated with immunosuppression |
-
2005
- 2005-11-15 AU AU2005307765A patent/AU2005307765C1/en active Active
- 2005-11-15 JP JP2007543209A patent/JP5341350B2/ja active Active
- 2005-11-15 US US11/667,713 patent/US7919093B2/en active Active
- 2005-11-15 CA CA 2588066 patent/CA2588066A1/en not_active Abandoned
- 2005-11-15 WO PCT/US2005/041594 patent/WO2006055665A2/en active Application Filing
- 2005-11-15 EP EP05851729A patent/EP1812473A4/en not_active Withdrawn
- 2005-11-15 EP EP20100153754 patent/EP2194144B1/en active Active
-
2011
- 2011-02-18 US US13/030,557 patent/US20110142821A1/en not_active Abandoned
-
2012
- 2012-07-30 JP JP2012168420A patent/JP2012233000A/ja active Pending
-
2014
- 2014-01-27 US US14/164,641 patent/US8956609B2/en active Active
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2008520241A5 (ja) | ||
JP2022031635A5 (ja) | ||
MX2009002711A (es) | Anticuerpos anti-receptor de folato alfa humanos y fragmentos de anticuerpo para la radioinmunoterapia de carcinoma de ovario. | |
NL300911I2 (nl) | sarilumab | |
HRP20130922T1 (hr) | U potpunosti humana protutijela protiv humanog 4-1bb (cd137) | |
WO2007062245A3 (en) | Human monoclonal antibody human cd134 (ox40) and methods of making and using same | |
JP2010507594A5 (ja) | ||
JP2007535490A5 (ja) | ||
HRP20170524T1 (hr) | Humana protutijela koja vežu humani protein 4 nalik angiopoietinu | |
JP2019504032A5 (ja) | ||
JP2009521496A5 (ja) | ||
JP2005515963A5 (ja) | ||
JP2006505545A5 (ja) | ||
JP2008516970A5 (ja) | ||
CY1113224T1 (el) | Νεο αντισωμα αντι-ρlgf | |
JP2013519364A5 (ja) | ||
AR052959A1 (es) | Anticuerpos anti- ccr5 y usos de los mismos | |
WO2008140653A3 (en) | Humaneered anti-factor b antibody | |
GT200500255A (es) | Anticuerpos anti-5ta humanizados y conjugados anticuerpo anti-5ta/calicheamicina | |
JP2009518005A5 (ja) | ||
JP2006524039A5 (ja) | ||
JP2014500009A5 (ja) | ||
JP2019525957A5 (ja) | ||
WO2006066568A3 (de) | Monokonale agonistische anti-ctla-4 antikörper | |
EP1790663A4 (en) | MONOCLONAL ANTIBODY (AD5-10) AGAINST THE TUMOR NEKROSIS FACTOR RELATED APOPTOSIS-INDUCING LIGAND RESPECTOR DR5, METHOD OF MANUFACTURE AND APPLICATIONS THEREOF |